A phase 2 randomized multicenter study of 2 extended dosing schedules of oral ezatiostat in low to intermediate-1 risk myelodysplastic syndrome

Oral Ezatiostat HCl (TLK199) and Myelodysplastic syndrome: A case report of sustained hematologic response following an abbreviated exposure

(2012) Fahd Quddus et al.   Journal of Hematology & Oncology

Glutathione transferases as mediators of signaling pathways involved in cell proliferation and cell death

(2010) E Laborde   CELL DEATH AND DIFFERENTIATION

The Epidemiology of Myelodysplastic Syndromes

(2010) Mikkael A. Sekeres   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

Phase 1 multicenter dose-escalation study of ezatiostat hydrochloride (TLK199 tablets), a novel glutathione analog prodrug, in patients with myelodysplastic syndrome

(2009) A. Raza et al.   BLOOD

Phase 1-2a multicenter dose-escalation study of ezatiostat hydrochloride liposomes for injection (Telintra(R), TLK199), a novel glutathione analog prodrug in patients with myelodysplastic syndrome

(2009) Azra Raza et al.   Journal of Hematology & Oncology

Molecular pathways in myelodysplastic syndromes and acute myeloid leukemia: relationships and distinctions-a review

(2008) Paolo Bernasconi   BRITISH JOURNAL OF HAEMATOLOGY

Characteristics of US Patients with Myelodysplastic Syndromes: Results of Six Cross-sectional Physician Surveys

(2008) Mikkael A. Sekeres et al.   JNCI-Journal of the National Cancer Institute